Dave Nellesen

Vice President

Dave Nellesen

Menlo Park

Education

M.B.A., Haas School of Business, University of California, Berkeley; Ph.D., molecular biology, University of California, San Diego; B.S., biochemistry, University of California, Los Angeles

Summary of Experience

Dr. Nellesen has broad experience in consulting, applying a range of strategies that address client needs in the development and commercialization of products for the biotechnology, pharmaceutical, molecular diagnostic, and medical device industries. He specializes in value proposition and evidence strategy, helping clients develop clinical and economic evidence of value to support launch strategy and secure favorable reimbursement. This work often includes published or unpublished evidence of the value of new products, including evidence dossiers (global value dossiers or AMCP dossiers) and related payer communication tools, health economic models, and peer-reviewed studies. He has also assisted clients in conducting primary research with payers and other stakeholders to assess the value of new technologies and evidence needed for favorable market access. In more than 15 years working in the biopharmaceutical industry, Dr. Nellesen has led a range of commercial strategy engagements, including strategic planning, intellectual property management and valuation, health care compliance, and business process improvement. Prior to joining Analysis Group, Dr. Nellesen worked as a consultant at PRTM and as a scientist and patent portfolio manager at Incyte Pharmaceuticals.

Selected Publishing

  • Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities

    Journal of Medical Economics, April 2014, Vol. 17, No. 4
    2014

    Truong HL, Nellesen D, Ludlam WH, Neary MP

      View abstract
    Health Care
  • Estimating the Incremental Net Health Benefit of Requirements for Cardiovascular Risk Evaluation for Diabetes Therapies

    Pharmacoepidemiology and Drug Safety, January 2014
    2014

    Chawla A, Mytelka D, McBride S, Nellesen D, Elkins B, Ball D, Kalsekar A, Towse A, Garrison L

      View article
    Health CareStrategy, Policy & Analytics
  • Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade

    Postgraduate Medicine, March 2013, Vol. 125, No. 2
    2013

    Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW

      View abstract
    Health Care
  • A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation

    Journal of Managed Care Pharmacy, November-December 2013, Vol. 19, No. 9
    2013

    Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT

      View article
    Health Care
  • Perspectives on Comparative Effectiveness Research: Views from Diverse Constituencies

    PharmacoEconomics, 2010, vol. 28, issue 10
    2010

    Nellesen DBirnbaum HGreenberg P

      View article
    Health Care
  • Personalized Medicine: Trends in Clinical Studies Based on National Registry Data

    ISPOR Poster, 2009
    2009

    Nellesen D, Person A, Yee K, Chawla A

      View article
    Health Care